薬理ゲノミクスと薬理プロテオミクスのジャーナル

概要

Solid Lipid Nanoparticles (SLN)

Theodora Roussou

Development of novel drug delivery has been a growing interest among the researchers. The novel drug delivery usually aims for maximal drug bioavailability, tissue targeting, controlled release kinetics, minimal immune response, ease of administration, and the effective delivery of traditionally difficult drugs such as lipophiles, amphiphiles and biomolecules. Colloidal drug carriers are one of the most acceptable approach to attain the goals of the novel drug delivery system. Colloidal drug carriers include vesicular drug
carriers and microparticulate drug carriers, which successfully prolong the existence of the drug in systemic circulation and lower the toxicity. A number of colloidal drug carriers such as liposomes, niosomes, pharmacosomes, virosomes, immunoliposomes, microparticles, nanoparticles, albumin microspheres have been developed, however, these carriers still have some draw-backs. To combat these drawbacks, Solid Lipid Nanoparticles (SLN) were introduced as a new class of colloidal drug carries. In this work, an overview about the definition, advantages, selection of ingredients and formulation techniques of the SLN is presented.